Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword
Pavlo Petakh(Kyiv School of Economics), Oleksandr Kamyshnyi(I.Horbachevsky Ternopil National Medical University), Rouan Yao(Norwegian University of Science and Technology), Iryna Kamyshna(I.Horbachevsky Ternopil National Medical University), Andriy Nykyforuk(Uzhhorod National University), John F. Imbery(University of Oslo), М. М. Корда(I.Horbachevsky Ternopil National Medical University), Valentyn Oksenych(University of Bergen)
Cited by 36
Related Papers
Effects of metformin on the gut microbiota: A systematic review
|Molecular Metabolism|2023|91
The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin
|Biomedicine & Pharmacotherapy|2023|70
Modulating Nitric Oxide: Implications for Cytotoxicity and Cytoprotection
|Antioxidants|2024|64
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
|Biomedicines|2024|51
Current treatment options for leptospirosis: a mini-review
|Frontiers in Microbiology|2024|48